The effectiveness of angiogenesis inhibitor drugs in the treatment of patients with age-related macular degeneration

Background.According to epidemiological studies, age-related macular degeneration (AMD) occupies a leading position among the causes of blindness and decreased visual acuity in the elderly. In recent decades, the latest methods of treatment of age-related macular degeneration have been developed. Scientists synthesized, and clinicians began to use drugs that suppress the production of endothelial vascular growth factor (VEGF), that is, in fact, they are antiangiogens. Despite the fact that the exact cause of the formation of the subretinal neovascular membrane in AMD has not been established, most scientists believe that VEGF plays a leading role in its formation. That is why the use of VEGF inhibitors is a very promising method of preventing the formation of newly formed vessels. Purpose. To evaluate the efficacy of angiogenesis inhibitors in the treatment of AMD. Material and methods. Outpatient charts of 40 patients (68 eyes) aged 60 to 85 years with the diagnosis of exudative form of AMD on the basis of one of the ophthalmologic clinics of Karaganda city for the period from 2019 to 2023 served as materials for the study. Results.The totality of the above examination results allows us to conclude that after angiogenesis inhibitor therapy, there was an improvement in the form of a decrease in retinal thickness in the area of edema, as well as a relative increase in visual acuity and the patient’s condition. Conclusion.The use of angiogenesis inhibitors has a positive effect on macular degeneration in terms of inhibition of neovascularization processes, as well as reduction of the existing macular edema and improvement of patients’ condition by increasing the visual ability of patients. Its global use is well justified, because when considering different scientific articles and analyzing patient reports even in one clinic, it can be concluded that this treatment method is very effective.